Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in J Urol Retrieve available abstracts of 130 articles: HTML format

Single Articles

November 2025
1. EIGL BJ, Elangovan A, Ghosh S, Kim JO, et al
   A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.
   J Urol. 2025;214:496-508.
   PubMed     Abstract available
   
   
   
2. KUMAR R, Lajkosz K, Hiemstra J, Finelli A, et al
   Characterizing the Impact of Novel Patient-Centered Pathology Reports on Men Undergoing Prostate Biopsy: The Patient-Centered Pathology Report Randomized Controlled Trial.
   J Urol. 2025;214:509-520.
   PubMed     Abstract available
   
   
   October 2025
3. KOKOROWSKI P, Friedrich NA, Luu M, Shiang A, et al
   Patient Participation in Consultations for Clinically Localized Prostate Cancer.
   J Urol. 2025 Oct 10:101097JU0000000000004814. doi: 10.1097/JU.0000000000004814.
   PubMed     Abstract available
   
   
   
4. FREITAS PFS, Khandekar A, Porto JG, Yu H, et al
   Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance Trial.
   J Urol. 2025;214:383-392.
   PubMed     Abstract available
   
   
   
5. DASKIVICH TJ, Stock SR, Cummings S, Masterson JM, et al
   Risks of Progression After Early Androgen Deprivation Therapy for Biochemical Recurrence After Radical Prostatectomy.
   J Urol. 2025;214:354-364.
   PubMed     Abstract available
   
   
   September 2025
6. MOSER AM, Elanjian A, Zamani A, Ginsburg KB, et al
   The risk of clinically significant prostate cancer on subsequent biopsies in men with HGPIN/ASAP on an MRI-informed index biopsy.
   J Urol. 2025 Sep 29:101097JU0000000000004797. doi: 10.1097/JU.0000000000004797.
   PubMed    
   
   
   
7. BORGES RC, Tourinho-Barbosa RR, Dias N, de Barros Pena Ribeiro Paiva G, et al
   Detection of Clinically Significant Prostate Cancer Using Micro-Ultrasound Versus MRI/Ultrasound Fusion Biopsy: A Propensity-Weighted Comparative Study.
   J Urol. 2025 Sep 26:101097JU0000000000004793. doi: 10.1097/JU.0000000000004793.
   PubMed     Abstract available
   
   
   
8. CHEN DC, Alhamdani Z, Papa N, Shen E, et al
   The Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
   J Urol. 2025 Sep 5:101097JU0000000000004734. doi: 10.1097/JU.0000000000004734.
   PubMed     Abstract available
   
   
   August 2025
9. ALVES-SANTIAGO M, Altuna-Coy A, Lopez-Ribelles P, Gil VA, et al
   A semen panel signature comprising sTWEAK Cytokine levels and expression of exomiR-221-3p and exomiR-222-3p for assessing prostate cancer prognosis, diagnostic utility, and detection of upgrading during active surveillance.
   J Urol. 2025 Aug 27:101097JU0000000000004749. doi: 10.1097/JU.0000000000004749.
   PubMed     Abstract available
   
   
   
10. JOYCE DD, Siemens DR
    Shared Decision-Making in Prostate Cancer Management: Easy to Say, Hard to Measure.
    J Urol. 2025 Aug 14:101097JU0000000000004698. doi: 10.1097/JU.0000000000004698.
    PubMed    
    
    
    
11. VICKERS A, Touijer K
    Letter: Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy Only.
    J Urol. 2025 Aug 12:101097JU0000000000004696. doi: 10.1097/JU.0000000000004696.
    PubMed    
    
    
    
12. LAZAROVICH A, Vigneswaran H, Palsdottir T, Eklund M, et al
    A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: Erratum.
    J Urol. 2025;214:238.
    PubMed    
    
    
    July 2025
13. ERAKY A, Tilu N, Ben-David R, Hug B, et al
    Diagnostic Accuracy of [(18)F]-DCFPyL PSMA PET/CT in Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy: Is Pelvic Lymph Node Dissection Still Necessary?
    J Urol. 2025 Jul 7:101097JU0000000000004659. doi: 10.1097/JU.0000000000004659.
    PubMed     Abstract available
    
    
    
14. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum.
    J Urol. 2025;214:111.
    PubMed    
    
    
    June 2025
15. DOMINGO MR, Seibert TM
    Reply: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.
    J Urol. 2025 Jun 20:101097JU0000000000004634. doi: 10.1097/JU.0000000000004634.
    PubMed    
    
    
    
16. FOGG RW, Krzastek SC, Vissichelli N, Defor E, et al
    Defining Abnormal Prostate Specific Antigen Values for Prostate Cancer Screening in the Spinal Cord Injury Population.
    J Urol. 2025 Jun 17:101097JU0000000000004644. doi: 10.1097/JU.0000000000004644.
    PubMed     Abstract available
    
    
    
17. LUO H, Guo J, Li H, Su H, et al
    Letter: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.
    J Urol. 2025 Jun 10:101097JU0000000000004624. doi: 10.1097/JU.0000000000004624.
    PubMed    
    
    
    
18. KAPLAN-MARANS E
    Letter: Prostate-Specific Antigen Density to Select Magnetic Resonance Imaging-Targeted vs Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study.
    J Urol. 2025 Jun 10:101097JU0000000000004625. doi: 10.1097/JU.0000000000004625.
    PubMed    
    
    
    
19. LEWICKI P, Borza T
    Editorial Comment: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer with Reliable Positive Predictive Value.
    J Urol. 2025 Jun 4:101097JU0000000000004621. doi: 10.1097/JU.0000000000004621.
    PubMed    
    
    
    
20. WAGGENER K, Snipes M, Rais-Bahrami S
    Editorial Comment on: "Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer with Reliable Positive Predictive Value".
    J Urol. 2025 Jun 4:101097JU0000000000004620. doi: 10.1097/JU.0000000000004620.
    PubMed    
    
    
    
21. SANDLOW S, Carbunaru S, Sun Z, Ofori B, et al
    Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making.
    J Urol. 2025;213:713-721.
    PubMed     Abstract available
    
    
    
22. SCUDERI S, Tin AL, Klug J, Porwal S, et al
    The Absolute Volume of Gleason Pattern 4 on Radical Prostatectomy Is More Strongly Associated With Advanced Stage and Biochemical Recurrence Than Gleason Grade Groups.
    J Urol. 2025;213:722-729.
    PubMed     Abstract available
    
    
    May 2025
23. REESE AC
    Editorial Comment: Pelvic Lymph Node Dissection in Prostate Cancer-is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection Vs Radical Prostatectomy On
    J Urol. 2025 May 23:101097JU0000000000004606. doi: 10.1097/JU.0000000000004606.
    PubMed    
    
    
    
24. DOMINGO MR, Do DD, Conlin CC, Bagrodia A, et al
    Restriction Spectrum Imaging as a quantitative biomarker for prostate cancer with reliable positive predictive value.
    J Urol. 2025 May 16:101097JU0000000000004611. doi: 10.1097/JU.0000000000004611.
    PubMed     Abstract available
    
    
    
25. LAZAROVICH A, Vigneswaran H, Palsdottir T, Eklund M, et al
    A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial.
    J Urol. 2025;213:590-599.
    PubMed     Abstract available
    
    
    
26. LI EV, Ren Y, Griffin J, Han J, et al
    An Artificial Intelligence-Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial.
    J Urol. 2025;213:600-608.
    PubMed     Abstract available
    
    
    
27. TOSOIAN JJ, Zhang Y, Meyers JI, Heaton S, et al
    Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine.
    J Urol. 2025;213:581-589.
    PubMed     Abstract available
    
    
    
28. MANNAS MP, Deng FM, Ion-Margineanu A, Freudiger C, et al
    Stimulated Raman Histology and Artificial Intelligence Provide Near Real-Time Interpretation of Radical Prostatectomy Surgical Margins.
    J Urol. 2025;213:609-616.
    PubMed     Abstract available
    
    
    April 2025
29. CHAPPIDI MR, Newcomb LF, Zheng Y, Liu M, et al
    Magnetic Resonance Imaging at second surveillance biopsy after diagnosis in patients with Grade Group 1 prostate cancer in the Canary Prostate Active Surveillance Study.
    J Urol. 2025 Apr 30:101097JU0000000000004592. doi: 10.1097/JU.0000000000004592.
    PubMed     Abstract available
    
    
    
30. FURRER MA, Sathianathen NJ, Mulholland CJ, Papa N, et al
    Pelvic lymph node dissection in prostate cancer - is it really necessary? A multicentric longitudinal study assessing oncological outcomes in prostate cancer patients undergoing pelvic lymph node dissection vs radical prostatectomy only.
    J Urol. 2025 Apr 28:101097JU0000000000004587. doi: 10.1097/JU.0000000000004587.
    PubMed     Abstract available
    
    
    
31. MARTIN SC, Gonzalez S, Kwan L, Delfin M, et al
    Evolution of Active Surveillance of Prostate Cancer: Impact of MRI, MRI-guided Biopsy and Focal Therapy.
    J Urol. 2025 Apr 21:101097JU0000000000004559. doi: 10.1097/JU.0000000000004559.
    PubMed     Abstract available
    
    
    
32. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025;213:538-540.
    PubMed    
    
    
    
33. BORDE T, Varble NA, Hazen LA, Saccenti L, et al
    Impact of Discordance Between Magnetic Resonance Imaging and Ultrasound Volume Measurements on Prostate Fusion Biopsy Outcomes.
    J Urol. 2025;213:428-436.
    PubMed     Abstract available
    
    
    March 2025
34. NI X, Sui J, Wang B, Wang H, et al
    Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS.
    J Urol. 2025 Mar 25:101097JU0000000000004545. doi: 10.1097/JU.0000000000004545.
    PubMed     Abstract available
    
    
    
35. ZHANG F, Li S
    Letter: A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.
    J Urol. 2025 Mar 6:101097JU0000000000004414. doi: 10.1097/JU.0000000000004414.
    PubMed    
    
    
    
36. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025 Mar 5:101097JU0000000000004491. doi: 10.1097/JU.0000000000004491.
    PubMed    
    
    
    February 2025
37. AHDOOT M, Naser-Tavakolian A, Heard JR, Williams C, et al
    PSA Density to Select MRI Targeted versus Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study.
    J Urol. 2025 Feb 14:101097JU0000000000004480. doi: 10.1097/JU.0000000000004480.
    PubMed     Abstract available
    
    
    
38. MARRA G, Barletta F, Scuderi S, Montefusco G, et al
    Adjuvant radiation therapy or observation with or without early salvage radiation therapy for men with node positive prostate cancer after surgery and negative pre-operative conventional imaging: a multicenter study.
    J Urol. 2025 Feb 10:101097JU0000000000004468. doi: 10.1097/JU.0000000000004468.
    PubMed     Abstract available
    
    
    
39. SHORE N
    Reply: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2025 Feb 10:101097JU0000000000004439. doi: 10.1097/JU.0000000000004439.
    PubMed    
    
    
    
40. 
    Novel Intraprostatic Magnetic Resonance-Guided Implantation of Multidrug-Eluting Microdevice for Testing of Systemic Therapy Agents In Situ: Proof of Concept in Intermediate-Risk and High-Risk Prostate Cancer: Erratum.
    J Urol. 2025;213:266.
    PubMed    
    
    
    
41. LI EV, Bennett R 4th, Ho A, Wong C, et al
    Clinical Factors Associated With Suspicious (18)F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL.
    J Urol. 2025;213:183-191.
    PubMed     Abstract available
    
    
    
42. LENFANT L, Taille Y, Chartier-Kastler E, Lukacs B, et al
    Artificial Urinary Sphincter Implants in Men: A National Health Care Data System-Based Study to Assess Reinterventions in France.
    J Urol. 2025;213:217-227.
    PubMed     Abstract available
    
    
    January 2025
43. KIM EH, Jing H, Utt KL, Vetter JM, et al
    An Artificial Intelligence Model Using Diffusion Basis Spectrum Imaging Metrics Accurately Predicts Clinically Significant Prostate Cancer.
    J Urol. 2025 Jan 27:101097JU0000000000004456. doi: 10.1097/JU.0000000000004456.
    PubMed     Abstract available
    
    
    
44. LUGHEZZANI G, Fasulo V, Lazzeri M
    Letter: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2025 Jan 24:101097JU0000000000004420. doi: 10.1097/JU.0000000000004420.
    PubMed    
    
    
    
45. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025;213:138-140.
    PubMed    
    
    
    December 2024
46. JONES JM, Matthew A, Tanguay S, Higano CS, et al
    A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.
    J Urol. 2024 Dec 20:101097JU0000000000004359. doi: 10.1097/JU.0000000000004359.
    PubMed     Abstract available
    
    
    
47. CANFIELD SE, George AK, Jue JS, Lewis SC, et al
    A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation.
    J Urol. 2024;212:862-872.
    PubMed     Abstract available
    
    
    
48. FLEVILLE S, O'Neill C, Safar D, Macleod A, et al
    Diagnostic Pathway Outcomes for Biparametric Magnetic Resonance Imaging-Targeted Lesions Using Cognitive Registration and Freehand Transperineal Prostate Biopsy in Biopsy-Naive Men (CRAFT Single-Center Study).
    J Urol. 2024;212:821-831.
    PubMed     Abstract available
    
    
    November 2024
49. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    High 11-ketotestosterone linked to shorter time to castration resistance in recurrent non-metastatic prostate cancer.
    J Urol. 2024 Nov 15:101097JU0000000000004333. doi: 10.1097/JU.0000000000004333.
    PubMed     Abstract available
    
    
    
50. NABI R, Zahid T, Farooqi HA
    Letter: Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Cente
    J Urol. 2024;212:762-763.
    PubMed    
    
    
    October 2024
51. FILON M, O'Neil B
    Can We Be Less Active in Prostate Cancer Surveillance?
    J Urol. 2024 Oct 16:101097JU0000000000004277. doi: 10.1097/JU.0000000000004277.
    PubMed    
    
    
    
52. FAKUNLE MO, Cowan JE, Washington SL 3rd, Shinohara K, et al
    Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer.
    J Urol. 2024 Oct 9:101097JU0000000000004265. doi: 10.1097/JU.0000000000004265.
    PubMed     Abstract available
    
    
    
53. BHANJI Y, Mamawala MK, Fletcher SA, Landis P, et al
    Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging?
    J Urol. 2024 Oct 2:101097JU0000000000004268. doi: 10.1097/JU.0000000000004268.
    PubMed     Abstract available
    
    
    
54. MA C
    Letter: Location-Based Oncological Outcomes of Sentinel Node Dissection in Radical Prostatectomy.
    J Urol. 2024;212:627-628.
    PubMed    
    
    
    
55. YAXLEY JW
    Letter: Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:628.
    PubMed    
    
    
    
56. CHOUDRY MM, Durant AM, Edmonds VS, Warren CJ, et al
    Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.
    J Urol. 2024;212:590-599.
    PubMed     Abstract available
    
    
    September 2024
57. FLORES JM, Vertosick EA, Salter CA, Benfante N, et al
    Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004267. doi: 10.1097/JU.0000000000004267.
    PubMed     Abstract available
    
    
    
58. STONE BV, Dominas CA, Bhagavatula SK, Ahn SW, et al
    Novel intraprostatic MR-guided implantation of multidrug-eluting microdevice for testing of systemic therapy agents in situ; Proof of concept in intermediate- and high-risk prostate cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004269. doi: 10.1097/JU.0000000000004269.
    PubMed     Abstract available
    
    
    
59. CARLSSON SV, Carroll PR, Hamdy FC
    Reevaluating the Definition of "Clinically Significant" Prostate Cancer as Grade Groups 2-5: An Imperative for Improved Risk Stratification.
    J Urol. 2024 Sep 17:101097JU0000000000004253. doi: 10.1097/JU.0000000000004253.
    PubMed    
    
    
    
60. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2024 Sep 16:101097JU0000000000004239. doi: 10.1097/JU.0000000000004239.
    PubMed    
    
    
    
61. SHORE ND, De Giorgi U, Freedland SJ
    Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.
    J Urol. 2024 Sep 3:101097JU0000000000004228. doi: 10.1097/JU.0000000000004228.
    PubMed    
    
    
    
62. GAFFNEY CD, Vertosick EA, Laudone V, Goh AC, et al
    Randomized Trial of Transverse vs Vertical Extraction Site Incision After Robotic Radical Prostatectomy.
    J Urol. 2024;212:401-408.
    PubMed     Abstract available
    
    
    
63. KLOTZ L
    The Genomics and Natural History of MRI-Visible vs MRI-Invisible Prostate Cancers: Clinical Implications.
    J Urol. 2024;212:494-498.
    PubMed    
    
    
    
64. MIAN BM, Kaufman RP Jr, Berstein A, Fisher HAG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;212:511-512.
    PubMed    
    
    
    
65. DROGHETTI M, Ozman O, Berrens AC, Piazza P, et al
    Location-Based Oncological Outcomes of Sentinel Node Dissection in Radical Prostatectomy.
    J Urol. 2024;212:409-419.
    PubMed     Abstract available
    
    
    
66. ZILLIOUX J, Camacho FT, Anderson RT, You W, et al
    Prevalence of Cognitive and Manual Dexterity Disorders Among Men Following Artificial Urinary Sphincter Placement.
    J Urol. 2024;212:441-450.
    PubMed     Abstract available
    
    
    August 2024
67. SUN R, Shan D
    Letter: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2024 Aug 23:101097JU0000000000004215. doi: 10.1097/JU.0000000000004215.
    PubMed    
    
    
    
68. BAHLER CD
    Reply: Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 Aug 12:101097JU0000000000004170. doi: 10.1097/JU.0000000000004170.
    PubMed    
    
    
    
69. SHORE N, Pieczonka C, Heron S, Gazi M, et al
    Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2024 Aug 9:101097JU0000000000004190. doi: 10.1097/JU.0000000000004190.
    PubMed     Abstract available
    
    
    
70. NIU S, Ding X, Liu B, Ao L, et al
    Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prosp
    J Urol. 2024;212:280-289.
    PubMed     Abstract available
    
    
    
71. VICKERS A, Vertosick E, Langsetmo L, Dahm P, et al
    Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts.
    J Urol. 2024;212:310-319.
    PubMed     Abstract available
    
    
    
72. SHORE N, Hafron J, Saltzstein D, Brown G, et al
    Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    J Urol. 2024 Aug 1:101097JU0000000000004163. doi: 10.1097/JU.0000000000004163.
    PubMed     Abstract available
    
    
    July 2024
73. LENI R, Vickers AJ, Brasso K, Montorsi F, et al
    Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark.
    J Urol. 2024 Jul 31:101097JU0000000000004159. doi: 10.1097/JU.0000000000004159.
    PubMed     Abstract available
    
    
    
74. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
    Letter: Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Jul 31:101097JU0000000000004171. doi: 10.1097/JU.0000000000004171.
    PubMed    
    
    
    
75. CIRULLI GO, Davis M, Stephens A, Chiarelli G, et al
    Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.
    J Urol. 2024 Jul 30:101097JU0000000000004118. doi: 10.1097/JU.0000000000004118.
    PubMed     Abstract available
    
    
    
76. ROY S, Sun Y, Chi KN, Ong M, et al
    Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial.
    J Urol. 2024 Jul 26:101097JU0000000000004158. doi: 10.1097/JU.0000000000004158.
    PubMed     Abstract available
    
    
    
77. MAI Z, Yan W
    Letter: Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 Jul 25:101097JU0000000000004155. doi: 10.1097/JU.0000000000004155.
    PubMed    
    
    
    
78. GIESEN A, Devos G, Everaerts W, Joniau S, et al
    Letter: A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024 Jul 8:101097JU0000000000004127. doi: 10.1097/JU.0000000000004127.
    PubMed    
    
    
    
79. RIVIERE P, Deshler LN, Morgan KM, Qiao EM, et al
    PSA Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age-Limits for Recommended Screening.
    J Urol. 2024 Jul 5:101097JU0000000000004138. doi: 10.1097/JU.0000000000004138.
    PubMed     Abstract available
    
    
    
80. MOTA SM, Priester A, Shubert J, Bong J, et al
    Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.
    J Urol. 2024;212:52-62.
    PubMed     Abstract available
    
    
    
81. MIAN BM, Bernstein A, Kaufman RP Jr, Fisher HAG, et al
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;212:227-228.
    PubMed    
    
    
    
82. NAHAS WC, Rodrigues GJ, Rodrigues Goncalves FA, Sawczyn GV, et al
    Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:32-40.
    PubMed     Abstract available
    
    
    
83. TILL C, Goodman PJ, Tangen C, Lucia MS, et al
    Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention Trial.
    J Urol. 2024;212:228-229.
    PubMed    
    
    
    June 2024
84. NANDALUR KR, Shen C, Zhao L, Al-Katib S, et al
    Association of Baseline MRI PI-RADS Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2024 Jun 25:101097JU0000000000004117. doi: 10.1097/JU.0000000000004117.
    PubMed     Abstract available
    
    
    
85. LEWICKI P, Morgan T
    The Genomics and Natural History of MRI Visible vs. Invisible Prostate Cancer: Clinical Implications".
    J Urol. 2024 Jun 12:101097JU0000000000004104. doi: 10.1097/JU.0000000000004104.
    PubMed    
    
    
    
86. MOSES RA, Hunter AE, Brandes ER, Zhang Z, et al
    Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
    J Urol. 2024;211:765-774.
    PubMed     Abstract available
    
    
    
87. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:802-803.
    PubMed    
    
    
    
88. SZABO RJ
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:801-802.
    PubMed    
    
    
    May 2024
89. BAHLER CD, Tachibana I, Tann M, Collins K, et al
    Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 May 24:101097JU0000000000004032. doi: 10.1097/JU.0000000000004032.
    PubMed     Abstract available
    
    
    
90. HUSSAIN J, Sanchez-Salas R
    Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
    PubMed    
    
    
    
91. EMMETT L, Papa N, Hope TA, Fendler W, et al
    Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
    J Urol. 2024 May 17:101097JU0000000000004010. doi: 10.1097/JU.0000000000004010.
    PubMed     Abstract available
    
    
    
92. TRINH QD, Labban M, Daniels D, Feldman A, et al
    Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color.
    J Urol. 2024 May 4:101097JU0000000000003931. doi: 10.1097/JU.0000000000003931.
    PubMed    
    
    
    
93. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
    J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
    PubMed     Abstract available
    
    
    
94. QIAN H, Chi C, Tricard T, Zhu Y, et al
    A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024;211:648-655.
    PubMed     Abstract available
    
    
    
95. MARIOTTI GC, Schmid BP, Gilberto GM, Garcia RG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707.
    PubMed    
    
    
    
96. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707-708.
    PubMed    
    
    
    April 2024
97. ST-LAURENT MP, Acland G, Hamilton SN, Hamm J, et al
    Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    J Urol. 2024 Apr 11:101097JU0000000000003965. doi: 10.1097/JU.0000000000003965.
    PubMed     Abstract available
    
    
    
98. RUMPF F, Plym A, Vaselkiv JB, Penney KL, et al
    Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Apr 10:101097JU0000000000003927. doi: 10.1097/JU.0000000000003927.
    PubMed     Abstract available
    
    
    
99. URABE F, Yoshioka T, Tashiro K, Kimura T, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:622.
    PubMed    
    
    
    
100. MIAN BM
     Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
     J Urol. 2024;211:623-624.
     PubMed    
     
     
     
101. CAKICI MC, Ozgur Kazan H, Yildirim A
     Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
     J Urol. 2024;211:624-625.
     PubMed    
     
     
     March 2024
102. LOEB S, Sanchez Nolasco T, Byrne N, Allen L, et al
     Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.
     J Urol. 2024;211:376-383.
     PubMed     Abstract available
     
     
     
103. FLORES JM, Vertosick E, Jenkins LC, Cooper J, et al
     Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
     J Urol. 2024;211:400-406.
     PubMed     Abstract available
     
     
     
104. MANNAS MP, Deng FM, Ion-Margineanu A, Jones D, et al
     Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies.
     J Urol. 2024;211:384-391.
     PubMed     Abstract available
     
     
     
105. HOUGEN HY, Sjoberg DD, Thomas J, Mahal BA, et al
     Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.
     J Urol. 2024;211:392-399.
     PubMed     Abstract available
     
     
     
106. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2024;211:502-503.
     PubMed    
     
     
     February 2024
107. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
     Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
     J Urol. 2024 Feb 19:101097JU0000000000003892. doi: 10.1097/JU.0000000000003892.
     PubMed     Abstract available
     
     
     
108. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
     Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
     J Urol. 2024 Feb 14:101097JU0000000000003890. doi: 10.1097/JU.0000000000003890.
     PubMed     Abstract available
     
     
     
109. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
     Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
     J Urol. 2024 Feb 14:101097JU0000000000003891. doi: 10.1097/JU.0000000000003891.
     PubMed     Abstract available
     
     
     
110. ESCOBAR AJ, Krishna S, Flowers KM, Abello A, et al
     Practical Use of Self-Adjusted Nitrous Oxide During Transrectal Prostate Biopsy: A Double-Blind Randomized Controlled Trial.
     J Urol. 2024;211:214-222.
     PubMed     Abstract available
     
     
     
111. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
     Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
     J Urol. 2024;211:205-213.
     PubMed     Abstract available
     
     
     
112. MISTRY NA, Sun Z, Sweis J, McCall C, et al
     Development and Validation of a Prostate Biopsy Risk Calculator in Black Men.
     J Urol. 2024;211:223-233.
     PubMed     Abstract available
     
     
     
113. BECHTEL MD, Michel C, Srinivasan P, Chalise P, et al
     Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression.
     J Urol. 2024 Feb 1:101097JU0000000000003849. doi: 10.1097/JU.0000000000003849.
     PubMed     Abstract available
     
     
     
114. BERNARDINO R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, et al
     Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through (18)F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients.
     J Urol. 2024 Feb 1:101097JU0000000000003850. doi: 10.1097/JU.0000000000003850.
     PubMed     Abstract available
     
     
     January 2024
115. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2024 Jan 15:101097JU0000000000003835. doi: 10.1097/JU.0000000000003835.
     PubMed    
     
     
     
116. GARNICK MB, Hafron J, Crawford ED
     Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
     J Urol. 2024 Jan 5:101097JU0000000000003831. doi: 10.1097/JU.0000000000003831.
     PubMed    
     
     
     December 2023
117. VAN NESTE L, Henao R, Wojno KJ, Signes J, et al
     Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
     J Urol. 2023 Dec 26:101097JU0000000000003824. doi: 10.1097/JU.0000000000003824.
     PubMed     Abstract available
     
     
     
118. STIRA J, Gravina C, Lombardo R, De Nunzio C, et al
     Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone?Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
     J Urol. 2023 Dec 22:101097JU0000000000003830. doi: 10.1097/JU.0000000000003830.
     PubMed    
     
     
     
119. REZAEE ME, Pallauf M, Fletcher SA, Han M, et al
     Risk of Biochemical Recurrence in Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension Treated with Radical Prostatectomy.
     J Urol. 2023 Dec 18:101097JU0000000000003825. doi: 10.1097/JU.0000000000003825.
     PubMed     Abstract available
     
     
     November 2023
120. TOSOIAN JJ, Yu A, Brisbane WG
     Innovation and Progress for Screening and Management of Localized Prostate Cancer-What an Exciting Time.
     J Urol. 2023 Nov 27:101097JU0000000000003797. doi: 10.1097/JU.0000000000003797.
     PubMed    
     
     
     
121. JOYCE DD, Filson CP, Herrel LA
     What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
     J Urol. 2023 Nov 27:101097JU0000000000003798. doi: 10.1097/JU.0000000000003798.
     PubMed    
     
     
     
122. PAGADALA MS, Ryan S, Carter H, Javier-DesLoges J, et al
     Comparison of Genomic Inflation Estimates in Genome-Wide Association Studies Using Genetically-Identified Ancestry versus Self-Identified Race/Ethnicity in Prostate Cancer Patients in ELLIPSE Cohort.
     J Urol. 2023 Nov 27:101097JU0000000000003794. doi: 10.1097/JU.0000000000003794.
     PubMed    
     
     
     
123. LEPOR H
     Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Reply.
     J Urol. 2023 Nov 15:101097JU0000000000003782. doi: 10.1097/JU.0000000000003782.
     PubMed    
     
     
     
124. CHEN Y, Liang Z, Yan W
     Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Letter.
     J Urol. 2023 Nov 14:101097JU0000000000003781. doi: 10.1097/JU.0000000000003781.
     PubMed    
     
     
     
125. SESSINE MS, Radoiu CS, Qi J, Labardee C, et al
     Can MRI Help Inform Which Men with a History of Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer?
     J Urol. 2023 Nov 6:101097JU0000000000003775. doi: 10.1097/JU.0000000000003775.
     PubMed     Abstract available
     
     
     
126. SINGHAL U, Hollenbeck BK, Kaffenberger SD, Salami SS, et al
     Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice.
     J Urol. 2023;210:771-777.
     PubMed     Abstract available
     
     
     October 2023
127. CRAWFORD ED, Hafron JM, Debruyne F, Wallis C, et al
     Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
     J Urol. 2023 Oct 5:101097JU0000000000003721. doi: 10.1097/JU.0000000000003721.
     PubMed     Abstract available
     
     
     
128. TERAMOTO Y, Wang Y, Miyamoto H
     Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?
     J Urol. 2023;210:639-648.
     PubMed     Abstract available
     
     
     September 2023
129. MONTORSI F, Gandaglia G, Salonia A, Briganti A, et al
     Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter.
     J Urol. 2023 Sep 6:101097JU0000000000003683. doi: 10.1097/JU.0000000000003683.
     PubMed    
     
     
     
130. SHAH N, Ioffe V
     Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
     J Urol. 2023 Sep 6:101097JU0000000000003682. doi: 10.1097/JU.0000000000003682.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.